29 March 2010, Melbourne and Sydney Australia: Immuron (ASX: IMC) has commenced a Phase II clinical trial of its immunotherapy product for the treatment of Metabolic Syndrome and NASH (Nonalcoholic steatohepatitis). The clinical trial is taking place at the Hadassah Hebrew University Medical Centre in Jerusalem under an agreement between Immuron and Hadasit, the Medical Centre’s commercialisati...
read more…